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Abstract
Background: Radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI) have been used for patients
with hepatocellular carcinoma (HCC). However, which therapy is superior remains to be further elucidated. We
aimed to conduct a systematic review to assess survival and local tumor recurrence rate with RFA compared with
PEI therapy for HCC.
Methods: We conducted systematic review and meta-analysis of randomized controlled trials (RCTs) published up
to 2014 in PubMed, MEDLINE, EMBASE, EBSCO, Springer, Ovid and the Cochrane library. Only RCTs that evaluated
survival rate and occurrence of HCC between RFA and PEI therapy were included. The OR (odds ratio) with a 95%
confidence interval (CI) was calculated by the Revman 5.0 software.
Results: A total of six studies including 983 HCC patients were eligible for this analysis. The survival rate showed a
significant benefit under RFA therapy over PEI at 1-year (P = 0.02, OR = 1.88, 95% CI: 1.09 to 3.22), 2-years (P = 0.0003,
OR = 2.06, 95% CI: 1.39 to 3.05) and 3-years (P = 0.0007, OR = 1.68, 95% CI: 1.25 to 2.27). Likewise, RFA achieved
significantly lower rates of local tumor recurrence over PEI at 1-year (P = 0.002, OR = 0.43, 95% CI: 0.26 to 0.73), 2-year
(P = 0.03, OR = 0.33, 95% CI: 0.12 to 0.88) and 3-year (P = 0.003, OR = 0.61, 95% CI: 0.43 to 0.84).
Conclusions: The current evidence suggests that RFA is superior to PEI in better survival and local disease control for
small HCCs <5 cm in diameter and that RFA is worthy of promotion in clinical applications.
Keywords: percutaneous radiofrequency ablation, percutaneous ethanol injection, small hepatocellular carcinoma,
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Background
Hepatocellular carcinoma (HCC) is the sixth leading
tumor in the world [1], and it is estimated that its inci-
dence will continue to rise in coming decades [2,3]. Ap-
proximately 80% to 90% of primary HCC is accompanied
by cirrhosis, which works together with HCC leading to
liver failure [4]. The pathogenesis for HCC is rather com-
plicated since many risk factors are involved.
At present, liver resection and transplantation can im-
prove the survival rate of HCC, but long waiting time
due to the shortage of donor organs may result in tumor
progression. Given these limitations, many nonsurgical
methods have been proposed, including percutaneous
ethanol injection (PEI), radiofrequency ablation (RFA),
microwave thermal ablation and percutaneous acid in-
jection. Among them, RFA is a localized thermal treat-
ment technique designed to produce tumor destruction
by heating tumor tissue to a temperature exceeding 50°C
[5]. With the development of this technique, RFA has
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recently gained greater interest and become the most
widely applied liver-directed treatment technique [6,7].
In recent years, several studies concerning the compari-
sons between therapies of RFA and PEI for HCC have
been published [8-10]. However, most of them did not
involve a comprehensive analysis of survival rate and oc-
currence of HCC in patients undergoing RFA and PEI
therapy. Although the meta-analysis of Bouza et al. has
analyzed survival rate and occurrence rate of HCC with
the two therapies, the sample size was relatively small.
In addition, the included studies in their meta-analysis
did not contain the latest studies on RFA [11].
Therefore, we conducted this study and aimed to per-
form a further systematic assessment on the efficacy of
treatment with percutaneous RFA and PEI on survival
and recurrence rates in patients with HCCs <5 cm in
diameter (1 to 3 nodules).
Methods
Literature search
A review of the literature was conducted in MEDLINE,
EMBASE, EBSCO, Springer, Ovid and the Cochrane li-
brary up to 2014 using the following key words: ‘hepato-
cellular carcinoma’ AND ‘HCC’ AND ‘radiofrequency
ablation’ AND ‘ethanol/alcohol injection’ with language
limited to English.
Inclusion criteria
To be eligible for this analysis, published articles had to
meet the following criteria: 1) all the patients were con-
firmed as HCC by pathological diagnosis and computed
tomography (CT) or magnetic resonance imaging (MRI)
diagnosis; 2) none of the patients had received any anti-
cancer treatments before; 3) all studies were randomized
controlled trials (RCTs)conducted on more than ten
adults; 4) tumor diameter was not more than 5 cm and le-
sion number was 1 to 3; and 5) all the results from the
studies were required to describe data related to at least
one of the following assessment indexes: 1-, 2- and 3-year-
survival rates or 1-, 2- and 3-year local tumor recurrence
rate.
Quality assessment
The Cochrane Handbook for Systematic Reviews of In-
terventions (http://handbook.cochrane.org) [12] was used
to evaluate the quality of the included studies independ-
ently by two investigators. Any disagreement was subse-
quently resolved by discussion with another investigator.
Data extraction
Two investigators independently extracted the following
data from original publications: 1) general information
including subject, authors, publication year and source
of the research; 2) details of the study design and dur-
ation of follow-up; and 3) the experimental results of ef-
ficacy including survival and recurrence rate. Software
Engauge Digitizer 4.1 (Geeknet, Inc., Mountain View,
California, US, http://digitizer. Sourceforge.net) was uti-
lized to extract data from survival curve as necessary.
Statistical analysis
Revman 5.0 (Cochrane Collaboration, Oxford, UK),
which was provided by the Cochrane Collaboration, was
used for meta-analysis and forest plot. The results were
presented as pooled odds ratio (OR) and 95% confidence
interval (CI). Chi-square and I2 test were performed to
determine the heterogeneity among studies. If no sig-
nificant heterogeneity was indicated (P >0.05, I2 <50%),
a fixed effects model was used in analysis. Otherwise
(P <0.05, I2 >50%), a random effects model was selected.
Figure 1 The flow chart of literature search and selection.




A total of 2,876 titles were retrieved (276 from MED-
LINE, 528 from EMBASE, 202 from EBSCO, 867 from
Springer, 984 from Ovid and 19 from the Cochrane li-
brary). Under the inclusion criteria, six studies including
983 HCC patients were selected [8-10,13-15]. Among
them, only three studies provided all the assessment in-
dexes [8,9,14], one study lacked a 2-year survival rate
and a 2-year local tumor recurrence rate [13], and one
lacked a 3-year survival rate and a 3-year local tumor re-
currence rate [15]. Furthermore, one study did not de-
scribe the 2-year local tumor recurrence rate [10]. All
these studies adopted a random method and allocation
concealment program, but no one mentioned whether
or not a double-blind method was used. The procedure
for literature selection was presented in Figure 1.
Survival rate
In our study, all of the six included studies assessed 1-
year survival rate [8-10,13-15], five studies assessed a 2-
year survival rate [8-10,14,15], and five studies assessed
a 3-year survival rate [8-10,13,14] of patients treated
with two types of therapies. The fixed effects model was
used to analyze the differences between two therapies on
survival rates for the absence of apparent heterogeneity
Figure 2 The survival rates evaluation between percutaneous radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI)
therapies. A) 1-year survival rate; B) 2-year survival rate; C) 3-year survival rate. CI, confidence interval; OR, odds radio. RFA, radiofrequency
ablation; PEI, percutaneous ethanol injection.
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(P >0.05, I2 <50%). Our results showed that patients
treated with RFA obtained a significantly higher survival
benefit in 1-year (P = 0.02, OR = 1.88, 95% CI: 1.09 to
3.22) (Figure 2A), 2-year (P = 0.0003, OR = 2.06, 95% CI:
1.39 to 3.05) (Figure 2B) and 3-year survival rate (P =
0.0007, OR = 1.68, 95% CI: 1.25 to 2.27) (Figure 2C) than
those treated with PEI.
Local tumor recurrence rate
In this meta-analysis, there was no apparent heterogen-
eity in 1-year (P = 0.57, I2 <50%) and 3-year (P = 0.60, I2
<50%) local tumor recurrence rate. On the contrary, sig-
nificant heterogeneity was presented in 2-year local
tumor recurrence rate (P = 0.01, I2 >50%). Therefore,
the fixed effects model was selected for 1- and 3-year
local tumor recurrence rate, while the random effects
model was applied to the 2-year rate. Further analysis
suggested that all the studies reported 1-year tumor
recurrence rate, up to four of the six studies assessed
2-year local tumor recurrence rate [8,9,14,15] and five
studies described 3-year local tumor recurrence rate
[8-10,13,14]. The results indicated that the 1-year
(P = 0.002, OR = 0.43, 95% CI: 0.26 to 0.73) (Figure 3A),
2-year (P = 0.03, OR = 0.33, 95% CI: 0.12 to 0.88)
(Figure 3B) and 3-year (P = 0.003, OR = 0.61, 95% CI:
0.43 to 0.84) (Figure 3C) local tumor recurrence rate of
HCC treated with RFA was significantly lower than that
with PEI.
Figure 3 The local tumor recurrence rates evaluation between percutaneous radiofrequency ablation (RFA) and percutaneous ethanol
injection (PEI) therapies. A) 1-year local tumor recurrence rate; B) 2-year local tumor recurrence rate; C) 3-year local tumor recurrence rate.
CI, confidence interval; OR, odds radio. RFA, radiofrequency ablation; PEI, percutaneous ethanol injection.
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Discussion
At present, RFA and PEI are verified to be feasible and
of benefit in non-operable patients and are used as
bridging therapies before liver transplantation [16,17]. In
recent years, many studies have demonstrated that RFA
is superior to PEI in efficacy and safety for the manage-
ment of HCC [13,18]. However, only a small fraction of
these studies were relevant to survival rate and tumor
recurrence rate [11]. Therefore, we performed this meta-
analysis to evaluate the efficacy of RFA and PEI for the
treatment of HCC patients by comparing their effects in
survival rates and local tumor recurrence rates.
In the present meta-analysis, a total of six studies were
selected in our analysis [8-10,13-15]. Our results showed
that treatment with RFA achieved higher survival rates
at 1, 2, and 3 years than treatment with PEI. In addition,
we further evaluated the local tumor recurrence rate,
and the results showed that treatment with RFA had a
lower risk of local tumor recurrence at 1, 2, and 3years
compared with PEI.
As far as we know, RFA was applied to the manage-
ment of HCC when the recurrent tumor was <6 cm in
diameter or when there were three or fewer tumor nod-
ules [19]. In contrast, PEI therapy is considered to be ef-
fective for the treatment of HCC of relatively small size
(less than 1 cm of necrosis) [20]. Due to this, RFA covers
a larger area in the treatment for HCC. Consistent with
this conclusion, the results of Shen A et al. demon-
strated that RFA appears superior to PEI in local tumor
control for small HCCs <3 cm in diameter [21]. In our
meta-analysis, the tumor sizes in the six studies were all
less than 5 cm in diameter. The higher survival rates
under RAF therapy compared with PEI, as indicated by
our results, can also be explained by the fact that RFA
has greater complete radiological tumor response
[22,23]. Moreover, tumor recurrence after RFA carries
significant prognostic value in relation to overall survival
[24]. Related studies have indicated that RFA can signifi-
cantly lower local tumor recurrence rates [25,26], which
is consistent with our results.
However, the following limitations of our meta-
analysis should be considered. First, the magnitude of in-
cluded studies and participants was relatively small. Sec-
ond, all of the included studies lacked of long-term data
on patient survival, and most of them have follow-up pe-
riods of approximately 2 to 3 years. Third, these studies
are limited to RCTs published in English, which may
have brought in publication bias. Fourth, a small propor-
tion of data were directly extracted from the survival
curves and local tumor recurrence curves without raw
data, which may reduce the accuracy of these data. In
addition, there was a shortage of subgroup analysis that
may contribute to 2-year local tumor recurrence rate.
Therefore, future studies should take tumor size, specific
site of the tumor and other subgroup effects into
consideration.
Conclusions
Based on this analysis, we conclude that RFA is more
advantageous than PEI therapy for HCC management
with respect to survival rate and local tumor recurrence
rate, and deserves to be applied to clinical practice.
Nevertheless, due to the limitations in our meta-analysis
as presented above, further validation regarding different
sizes of tumor therapy should be obtained in more ran-
domized studies comparing RFA and PEI.
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